Executives and directors of the West Lafayette-based biotech hold nearly 9 percent of Endocyte stock, worth about $177 million, based on the deal price of $24 a share.
According to the air permit application, the plant would have annual emissions of about 2.2 million tons of carbon dioxide, 225 tons of carbon monoxide and 120 tons of sulfur dioxide.
Overseeing Eli Lilly and Co.’s philanthropic work in the United States, Kenya and Mexico, Courtney Roberts also leads a pilot program to address barriers to diabetes care in three local neighborhoods.
The highly interactive and sophisticated Blue Room at this year’s National FFA Convention & Expo knocked the socks off thousands of students at the Indiana Convention Center. The initiative to highlight the advances in agricultural technology will continue year-round online.
The President’s son made a stop in the Hoosier state Monday at a Republican rally, making a pitch for Senate candidate Mike Braun and 6th District congressional candidate Greg Pence.
Risk tolerance, risk capacity and risk perception are the fundamental elements of your risk profile. The best way to construct your portfolio and ensure you can hang on for the whole ride is when you evaluate and discuss these risk elements individually and not as a composite assessment.
The West Lafayette biotech firm’s stock traded as low as $1.41 last fall, following multiple setbacks and restructurings. But the stock had soared to $24 Thursday morning after news that it would be acquired by Novartis.
Shares in Elanco Animal Health Inc. slipped as much as 3.3 percent Monday morning after lead managers and other banks involved in its recent initial public offering started coverage on the animal health company.
Tens of millions of Social Security recipients and other retirees will get a boost in benefits next year. It's the biggest increase most retired baby boomers have gotten.
Allison Transmission is concerned its specialized combat-vehicle transmission production line, which accounts for more than $100 million in annual revenue, is under threat.
The company, which employs more than 3,000 on the northeast side, has been struggling on the diabetes side of its business. To bounce back, it is investing heavily in diagnostics, and is working to commercialize several products it hopes will be game-changers.
